Peptide · Fact sheet

Bremelanotide

Also known as Vyleesi · PT-141

Bremelanotide is FDA approved for a specific diagnosis: acquired, generalized hypoactive sexual desire disorder in premenopausal women when the low desire is not explained by another condition, relationship problem, or medication. It is not approved to enhance sexual performance or for use in men or postmenopausal women.

FDA approved for specific usesStrong human evidence for approved uses

What is Bremelanotide?

Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors involved in central nervous system signaling.

Its approval is tied to a defined diagnosis, population, product, and outcome—not the broader online label PT-141.

Benefits & claims

It is an unusual approved peptide that acts through central desire pathways rather than directly changing blood flow.

Online claims often erase the label's population limits and significant cardiovascular, nausea, and pigmentation warnings.

What the evidence supports

  • Phase 3 trials found modest average improvements in sexual desire and distress compared with placebo in the labeled population.
  • The clinical goal is diagnosis-specific improvement, not a general enhancement claim.
Research areas
  • Hypoactive sexual desire disorder
  • Sexual desire and related distress
  • Melanocortin signaling
  • Other sexual-function populations outside the approved label

Dosage & frequency

Product-specific label information

Vyleesi has an as-needed labeled regimen for a specific sexual-desire disorder in premenopausal women. It is not approved for men or general sexual performance.

Vyleesi

Premenopausal women with acquired, generalized HSDD

Amount
1.75 mg
Frequency
As needed, at least 45 minutes before sexual activity; no more than one dose per 24 hours; more than eight doses per month is not recommended
Route studied or labeled
Subcutaneous

Labeled disorder-specific use; cardiovascular contraindications apply.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • The approved bremelanotide product is distinct from melanotan II.

Interactions & precautions

  • Delayed gastric emptying can affect oral medicines; the label specifically cautions about oral naltrexone.

What is still unresolved

  • The label does not establish a predictable duration of sexual-response benefit.

Side effects & risks

  • The label warns about transient increases in blood pressure and reductions in heart rate and contraindicates use with uncontrolled hypertension or known cardiovascular disease.
  • Nausea was common in pivotal trials; flushing, headache, vomiting, and injection-site reactions also occurred.
  • Focal hyperpigmentation may occur and did not always resolve after stopping treatment in studies.
  • The product can affect absorption of some oral medicines through delayed gastric emptying.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Two randomized Phase 3 trials support the scoped indication, with improvements in desire and distress measures. Evidence does not establish a universal libido or performance effect.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Pain: reported experiences

Mixed account · personal report

Persistent nausea with little perceived desire benefit

After a single reported PT-141 exposure, an author described nausea that continued into the following day, back and neck tension, and little increase in desire. A stronger morning erection was difficult to distinguish from their usual experience.

Reported use in this account

Product
Product described as PT-141; identity unverified
Amount
1 mg
Frequency
One reported administration
Route
Not specified clearly
Duration
One administration with a next-day follow-up

Other exposures described: BPC-157, used for a week according to the author

The author also reported BPC-157 exposure and usual morning erections. Product contents and the cause of nausea or pain were not independently verified; no administration route was stated.

Read the single-exposure account

Approval status

Vyleesi is FDA approved for acquired, generalized hypoactive sexual desire disorder in specified premenopausal women. The label explicitly excludes sexual-performance enhancement and use in men or postmenopausal women.

Approved uses

  • Acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women under the Vyleesi label

FDA approved for a specific sexual-desire disorder indication

Bremelanotide is approved under the Vyleesi label for a defined indication and population. That status does not make it a general libido, mood, or performance treatment.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Benefit-risk balance in populations outside the label
  • How well average trial changes translate into meaningful benefit for an individual
  • Long-term outcomes with broader or more frequent exposure than studied

Summary

Bremelanotide is an approved peptide medicine, but the approved use is much narrower than the online PT-141 conversation. Diagnosis, population, cardiovascular risk, and the exact label matter.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Vyleesi

    Official indication, limitations, contraindications, warnings, and adverse reactions.

  2. fdaFDA multidisciplinary review: Vyleesi

    FDA's clinical and regulatory assessment supporting the approval.

  3. pubmedRECONNECT Phase 3 trials

    Peer-reviewed report of the two pivotal randomized trials.

  4. nihVyleesi current prescribing information

    Primary source for the practical reference information.

How we assess sources · Suggest a correction